| Closed |
S1607 |
T-VEC + Pembro in Adv Melanoma follow prog on PD-1 Inhibitor |
10/2/2017 |
11/1/2020 |
67% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
S1619 |
Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab |
11/3/2017 |
5/1/2020 |
100% |
|
|
| Closed |
S1612 |
Older AML |
12/22/2017 |
|
5% |
|
|
| Closed |
S1400K |
Lung-MAP S1400K: c-MET Positive |
2/5/2018 |
12/21/2018 |
64% |
|
|
| Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
| Open |
S1703 |
Disease Monitoring Study |
7/16/2018 |
|
46% |
|
|
| Closed |
S1712 |
Rando PhII Ruxolitinib + BCR-ABL TKIs in CML w/Molecular Disease |
7/20/2018 |
|
96% |
|
|
| Closed |
S1701 |
Thymic |
8/9/2018 |
9/29/2022 |
32% |
|
|
| Open |
S1706 |
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast |
9/12/2018 |
|
52% |
|
|
| Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
63% |
|
|
| Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
| Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
| Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
| Closed |
S1900A |
LUNGMAP S1900A: LOH HIGH and/or BRCA 1/2 mutation - Rucaparib |
1/29/2019 |
|
73% |
|
|
| Closed |
S1600 |
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes |
2/21/2019 |
10/20/2023 |
100% |
|
|
| Closed |
S1614 |
Rando Prophylactic Antiviral HBV |
2/21/2019 |
11/15/2022 |
1% |
|
|
| Closed |
S1714 |
CIPN |
3/1/2019 |
|
100% |
|
|
| Closed |
S1806 |
Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer. |
4/19/2019 |
|
100% |
|
|
| Closed |
S1800A |
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study |
5/17/2019 |
11/16/2020 |
100% |
|
|
